Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday. The company’s shares closed ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 6.4% year on year to $7.57 billion. The company expects ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% in the company’s quarterly cash dividend, beginning in the first ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share ...

Gilead Sciences, a leader in HIV drugs, faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033, making diversification crucial. The current stock price at $95+ implies 5 ...

Also Read: Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments The HIV drug maker reported third-quarter sales of $7.55 billion, up 7% year over ...

Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...